RPL31

Across TCGA pan-cancer cohorts, RPL31 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RPL31 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPL31 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPL31 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, HNSC, and GBM are the cancer types where RPL31 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.708	0.967	.004	39	view →
HNSC	OS	Median	All	1.000	0.449	.023	10	view →
GBM	DFS	Median	All	0.287	0.456	.014	10	view →
LUAD	OS	Tertile	All	0.833	0.627	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RPL31–CCRCC (OS)

Open the CCRCC breakdown →